The effect cannabidiol has on Lennox-Gastaut syndrome may be explained by the drug-drug interaction between CBD and anti-seizure medication.
A new study reports a 39 to 46% reduction in seizures in children with Dravet syndrome and Lennox-Gastaut syndrome when given CBD based treatments.
Researchers say a new cannabis derived drug, which is expected to receive full approval from the FDA this week, will be a vital intervention for children with Dravet Syndrome and Lennox-Gastaut syndrome.
Researchers provide further evidence that the cannabis compound, CBD, is effective at reducing seizures in people with epilepsy. The new study reveals CBD significantly reduced seizures in people with Lennox-Gastaut syndrome. Previously, the researchers demonstrated CBD was effective at seizure control in Dravet syndrome.
A new study in The Lancet reports coupling cannabidiol with other anti-epilepsy treatments can help reduce the number of seizures in those with Lennox-Gastaut syndrome, a treatment resistant form of epilepsy.
Cannabidiol could help cut seizures by half in children and adults with Lennox-Gastaut syndrome, an extremely severe form of epilepsy, researchers report.
A new study reviews the use of medical marijuana as a potential treatment for childhood seizures.
Researchers report cannabidiol could help treat children with severe epilepsy who have not responded to other therapies.
